Boston Scientific Corp (BSX): Timothy A. Pratt , EVP, GC & Chief Admin Officer of Boston Scientific Corp sold 24,229 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $22.66 per share for a total value of $548,975.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, Keith D Dawkins (EVP, Global Chief Med. Off.) sold 80,000 shares at $22.15 per share price.On May 12, 2016, John Bradley Sorenson (SVP, Manuf & Sup Chn) sold 2,800 shares at $22.15 per share price.Also, On May 9, 2016, Jeffrey B. Mirviss (SVP&Pres, Periph Intervent) sold 24,659 shares at $21.94 per share price.On May 4, 2016, Joseph Michael Fitzgerald (EVP & President, CRM) sold 79,960 shares at $21.81 per share price.
Shares of Boston Scientific Corporation (BSX) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.19 points or -0.83% at $22.8 with 1,30,65,059 shares getting traded. Post opening the session at $22.98, the shares hit an intraday low of $22.725 and an intraday high of $22.99 and the price vacillated in this range throughout the day. The company has a market cap of $30,937 M and the number of outstanding shares has been calculated to be 1,35,68,66,900 shares. The 52-week high of Boston Scientific Corporation is $23.03 and the 52-week low is $14.1801.
Company has been under the radar of several Street Analysts.Boston Scientific Corporation is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $22 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $22 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Wedbush to Neutral and the brokerage firm has raised the Price Target to $ 23 from a previous price target of $19 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $23 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 22 from a previous price target of $20 .The Rating was issued on Apr 27, 2016.
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.